RecruitingNot ApplicableNCT05224726

Platelet Rich Plasma for Uterine Scar

Platelet Rich Plasma for the Treatment of Uterine Scar


Sponsor

The University of Texas Health Science Center, Houston

Enrollment

40 participants

Start Date

Jul 19, 2025

Study Type

INTERVENTIONAL

Conditions

Summary

When vessel wall injury occurs, platelets become activated, releasing more than 30 bioactive proteins, many of which have a fundamental role in hemostasis, inflammation and ultimate wound healing. Platelet-rich plasma (PRP), a modification of fibrin glue made from autologous blood, is being used to deliver growth factors in high concentration to sites requiring wound healing. PRP is obtained from a sample of patients' blood drawn at the time of treatment. As the rate of cesarean deliveries has been rising, long-term adverse sequelae due to uterine scar defects have been increasing. PRP might be a simple preventive treatment that potentially can reduce morbidity following cesarean deliveries.


Eligibility

Sex: FEMALEMin Age: 18 YearsMax Age: 52 Years

Inclusion Criteria2

  • Women undergoing elective cesarean delivery
  • Term pregnancy (≥37 weeks of gestation)

Exclusion Criteria4

  • Thrombocytopenia (CBC Platelet count \<70,000)
  • Connective tissue disease
  • Uterine scars other than cesarean (s/p myomectomy, s/p cornual resection)
  • Malformed uterus (unicornuate, bicornuate, didelphic)

Interested in this trial?

Get notified about updates and connect with the research team.

Interventions

OTHERPlatelet Rich Plasma

Injection of 5cc of PRP preparation at the myometrium around the uterine incision after it has been sutured.

OTHERPlacebo

Injection of 5cc of 0.9% Normal Saline at the myometrium around the uterine incision after it has been sutured.


Locations(1)

Sheba Medical Center

Ramat Gan, Center, Israel

View Full Details on ClinicalTrials.gov

For the most up-to-date information, visit the official listing.

Visit

NCT05224726


Related Trials